Close Menu

genome mapping

The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.

The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.

The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.